The risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. Popular framing reduces it to “antipsychotics cause stroke in dementia” — a true sentence that flattens a multi-axis decision. Choma’s 2025 analysis of UK primary care records is the largest …
SSRIs raise bleeding risk on their own. DOACs (direct oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban) raise it more. The intuitive worry is that combining them stacks the two effects. A new BJGP Open analysis from Chau and colleagues argues the stacking is smaller than most popular framings claim, and that the real safety question …
Lithium prescribing during pregnancy sits in a knot of competing risks. The teratogenicity data have been recalibrated dramatically since the 1970s, while the postpartum-relapse data have moved in the opposite direction. Most popular framing still treats lithium as a uniquely dangerous fetal exposure to be avoided when possible. The new Chauhan UK cohort shows what …
For two decades, headlines have linked autism to maternal obesity, depression, anxiety, gestational diabetes, infection, autoimmune disease, and antidepressant use. The studies behind those headlines are well-replicated registry associations. A new design from the Aarhus University iPSYCH group offers the most careful answer yet to what they mean for an individual pregnancy. Most “maternal X …
Research Highlights One published case is not a base rate. Roelandt and colleagues (2026) describe a 25-year-old multimorbid patient who developed severe ketamine addiction after a single 75 mg intranasal sub-anesthetic dose given for acute suicidality. It is N = 1, but it is now the second published case after Bonnet 2015 of post-clinical-use ketamine …
Research Highlights People with schizophrenia die 15–20 years earlier on average (SMR 2.5–3.5x), develop dementia roughly 20 years earlier, and show metabolic disease in their 20s and 30s. The 2008 “accelerated aging” hypothesis was coined to explain that pattern.1,6,7 A 2026 systematic review of 170 studies argues “advanced aging” fits better than “accelerated aging,” with …
Research Highlights GLP-1 receptor agonists are diabetes drugs (Ozempic, Trulicity, Byetta) being tested in Parkinson’s disease for possible disease-modifying effects. The hypothesis: shared metabolic-inflammatory pathways between type 2 diabetes and Parkinson’s mean drugs that work for one might help the other. A 2026 network meta-analysis pooled 5 trials and 708 patients. Pairwise analysis showed no …